Click to view a price quote on ADPT. : Shares of Adaptive Biotechnologies, (ADPT) the Seattle company seeking to use the genetics of the immune system in life-sciences research and drug development, nearly doubled on Thursday, their first day of trading. On Wednesday Adaptive priced an IPO of 15 million shares at $20, exceeding the estimated range of $18 to $19 a share and an earlier estimate of $15 to $17. Joint lead book-running managers for the transaction were Goldman Sachs, JP Morgan and Bank of America Merrill Lynch.